1. �й�ҽѧ��ѧԺƤ�����о���
2. �Ͼ���ѧ

HIV���кͿ��������HIV���������ϲ�����ϲ�������ϸ���Ŀ��塣HIV�кͿ���İ�λ�Dz�����Ĥ��������Щ��ϸ�������Ϻ�Ĥ�ں��йص����򣬿���Ľ������ص��׵Ĺ��������أ�Ŀǰ������о�Ϊ��HIVҩ���ɱ΢������������ṩ�����ۻ�����HIV���������кͿ������������ˣ�Ϊ�����Ч�����磬��Ҫ�Կ�ԭ����������ƣ��Ա����Ч���յ������кͿ��塣����HIV��������ƣ��кͿ���������ؼ����ס��е��Լ���HIV�����о��Ĺ�ϵ�ͽ�չ��

Neutralizing antibodies specific for HIV can bind to the virus and inhibit HIV entry into host cells. The targets of HIV-specific neutralizing antibodies are the sites associated with receptor binding or membrane fusion on the envelop proteins of HIV. Relevant studies have provided theoretical basis for developing anti-HIV medicines and microbicides. The neutralization is sensitive to the conformation of related proteins. On the other hand, HIV has a latent ability to escape from antibodies neutralization. Therefore, the rational design of antigen to induce broad-spectrum neutralizing antibodies is necessary for the development of successful vaccines. This paper introduces HIV invasion mechanism as well as the relationship of HIV neutralizing antibodies with entry-related crucial proteins��targets and anti-HIV vaccines.

[1] Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS[J]. Science, 1984,224(4648): 500-503. [2] Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target[J]. Science, 2009,326(5950): 285-289. [3] Deeks SG, Schweighardt B, Wrin T, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses[J]. J Virol, 2006,80(12): 6155-6164. [4] Nabel GJ. Immunology. Close to the edge: neutralizing the HIV-1 envelope[J]. Science, 2005,308(5730): 1878-1879. [5] Letvin NL. Virology. Moving forward in HIV vaccine development[J]. Science, 2009,326(5957): 1196-1198. [6] Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies[J]. Proc Natl Acad Sci U S A, 2009,106(48): 20234-20239. [7] Sun ZY, Oh KJ, Kim M, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane[J]. Immunity, 2008,28(1): 52-63. [8] Verkoczy L, Diaz M, Holl TM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance[J]. Proc Natl Acad Sci U S A, 2010,107(1): 181-186. [9] Song L, Sun ZY, Coleman KE, et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface[J]. Proc Natl Acad Sci U S A, 2009,106(22): 9057-9062. [10] Calarese DA, Lee HK, Huang CY, et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12[J]. Proc Natl Acad Sci U S A, 2005,102(38): 13372-13377. [11] Duenas-Decamp MJ, Clapham PR. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody, 2G12[J]. J Virol, 2010. [12] Mester B, Manor R, Mor A, et al. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D[J]. Biochemistry, 2009,48(33): 7867-7877. [13] Eda Y, Murakami T, Ami Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection[J]. J Virol, 2006,80(11): 5563-5570. [14] Joyce JG, Krauss IJ, Song HC, et al. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions[J]. Proc Natl Acad Sci U S A, 2008,105(41): 15684-15689. [15] Dunlop DC, Bonomelli C, Mansab F, et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans[J]. Glycobiology, 2010,20(7): 812-823. [16] Shibata J, Yoshimura K, Honda A, et al. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate[J]. J Virol, 2007,81(8): 3757-3768. [17] Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines[J]. Annu Rev Immunol, 2010,28: 413-444. [18] Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem[J]. Nat Immunol, 2004,5(3): 233-236. [19] Grundner C, Mirzabekov T, Sodroski J, et al. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins[J]. J Virol, 2002,76(7): 3511-3521. [20] Wu X, Yang ZY, Li Y, et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1[J]. Science, 2010. [21] Zhou T, Georgiev I, Wu X, et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01[J]. Science, 2010. [22] Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies[J]. Nat Med, 2007,13(9): 1032-1034. [23] Bianchi E, Joyce JG, Miller MD, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates[J]. Proc Natl Acad Sci U S A, 2010,107(23): 10655-10660.